ARTICLE | Company News
Miltenyi acquires Living Pharma and its CAR T technology
July 28, 2017 8:23 PM UTC
The Lentigen Technology Inc. subsidiary of Miltenyi Biotec GmbH (Bergisch Gladbach, Germany) acquired immunotherapy company Living Pharma Inc. (Baltimore, Md.), gaining Living Pharma’s preclinical Anti-Tag CAR (AT-CAR) engineered T cell therapy technology. The companies will continue developing AT-CAR technology using Lentigen’s lentiviral vector technologies. A Miltenyi spokesperson said clinical trials of the product are expected in hematological cancers within one to two years. The companies declined to disclose financial terms...
BCIQ Company Profiles